Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.33 |
| ▸ | EML4 | Q9HC35 | 5/20 | 0.33 |
| ▸ | RET | P07949 | 4/20 | 0.33 |
| ▸ | ROS1 | P08922 | 4/20 | 0.33 |
| ▸ | FLT3 | P36888 | 4/20 | 0.33 |
| ▸ | SYK | P43405 | 4/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944971 | 0.92 | RET (0.41) | ALKEML4RETROS1FLT3 | |
| SCHEMBL30205554 | 0.92 | RET (0.41) | ALKEML4RETROS1FLT3 | |
| SCHEMBL30205996 | 0.90 | LRRK2 (0.36) | EGFRALKEML4RETROS1 | |
| SCHEMBL30206216 | 0.89 | EGFR (0.33) | EGFRALKSYKPLK1JAK3 | |
| SCHEMBL30206188 | 0.89 | EGFR (0.32) | EGFRALKEML4RETROS1 | |
| SCHEMBL30206228 | 0.89 | ALK (0.33) | EGFRALKEML4RETROS1 | |
| SCHEMBL29173389 | 0.89 | EGFR (0.33) | EGFRALKSYKPLK1JAK3 | |
| SCHEMBL30206202 | 0.87 | PKMYT1 (0.40) | ALKEML4RETROS1FLT3 | |
| SCHEMBL29173512 | 0.87 | PKMYT1 (0.40) | ALKEML4RETROS1FLT3 | |
| SCHEMBL29173637 | 0.85 | ALDH1A1 (0.39) | EGFRALKEML4FLT3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | EGFR 2072/4885MAP4K4 86/4885TNIK 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.